IBDEI1FH ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25327,1,5,0)
 ;;=5^HX-PROSTATIC MALIGNANCY
 ;;^UTILITY(U,$J,358.3,25327,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,25328,0)
 ;;=V10.47^^147^1587^43
 ;;^UTILITY(U,$J,358.3,25328,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25328,1,4,0)
 ;;=4^V10.47
 ;;^UTILITY(U,$J,358.3,25328,1,5,0)
 ;;=5^HX-TESTICULAR MALIGNANCY
 ;;^UTILITY(U,$J,358.3,25328,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,25329,0)
 ;;=V10.48^^147^1587^48
 ;;^UTILITY(U,$J,358.3,25329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25329,1,4,0)
 ;;=4^V10.48
 ;;^UTILITY(U,$J,358.3,25329,1,5,0)
 ;;=5^PSNL HX MAL NEOPL-EPIDID
 ;;^UTILITY(U,$J,358.3,25329,2)
 ;;=^321226
 ;;^UTILITY(U,$J,358.3,25330,0)
 ;;=V10.49^^147^1587^33
 ;;^UTILITY(U,$J,358.3,25330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25330,1,4,0)
 ;;=4^V10.49
 ;;^UTILITY(U,$J,358.3,25330,1,5,0)
 ;;=5^HX-MALE GENIT MALIG NEC
 ;;^UTILITY(U,$J,358.3,25330,2)
 ;;=^295226
 ;;^UTILITY(U,$J,358.3,25331,0)
 ;;=V10.50^^147^1587^46
 ;;^UTILITY(U,$J,358.3,25331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25331,1,4,0)
 ;;=4^V10.50
 ;;^UTILITY(U,$J,358.3,25331,1,5,0)
 ;;=5^HX-URINARY MALIGNAN NOS
 ;;^UTILITY(U,$J,358.3,25331,2)
 ;;=^295227
 ;;^UTILITY(U,$J,358.3,25332,0)
 ;;=V10.51^^147^1587^1
 ;;^UTILITY(U,$J,358.3,25332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25332,1,4,0)
 ;;=4^V10.51
 ;;^UTILITY(U,$J,358.3,25332,1,5,0)
 ;;=5^HX OF BLADDER MALIGNANCY
 ;;^UTILITY(U,$J,358.3,25332,2)
 ;;=^295228
 ;;^UTILITY(U,$J,358.3,25333,0)
 ;;=V10.52^^147^1587^10
 ;;^UTILITY(U,$J,358.3,25333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25333,1,4,0)
 ;;=4^V10.52
 ;;^UTILITY(U,$J,358.3,25333,1,5,0)
 ;;=5^HX OF KIDNEY MALIGNANCY
 ;;^UTILITY(U,$J,358.3,25333,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,25334,0)
 ;;=V10.53^^147^1587^15
 ;;^UTILITY(U,$J,358.3,25334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25334,1,4,0)
 ;;=4^V10.53
 ;;^UTILITY(U,$J,358.3,25334,1,5,0)
 ;;=5^HX OF MAL NEOPLASM,RENAL PELVIS
 ;;^UTILITY(U,$J,358.3,25334,2)
 ;;=^323624
 ;;^UTILITY(U,$J,358.3,25335,0)
 ;;=V10.59^^147^1587^45
 ;;^UTILITY(U,$J,358.3,25335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25335,1,4,0)
 ;;=4^V10.59
 ;;^UTILITY(U,$J,358.3,25335,1,5,0)
 ;;=5^HX-URINARY MALIGNAN NEC
 ;;^UTILITY(U,$J,358.3,25335,2)
 ;;=^295230
 ;;^UTILITY(U,$J,358.3,25336,0)
 ;;=V10.60^^147^1587^12
 ;;^UTILITY(U,$J,358.3,25336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25336,1,4,0)
 ;;=4^V10.60
 ;;^UTILITY(U,$J,358.3,25336,1,5,0)
 ;;=5^HX OF LEUKEMIA NOS
 ;;^UTILITY(U,$J,358.3,25336,2)
 ;;=^295231
 ;;^UTILITY(U,$J,358.3,25337,0)
 ;;=V10.61^^147^1587^14
 ;;^UTILITY(U,$J,358.3,25337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25337,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,25337,1,5,0)
 ;;=5^HX OF LYMPHOID LEUKEMIA
 ;;^UTILITY(U,$J,358.3,25337,2)
 ;;=^295232
 ;;^UTILITY(U,$J,358.3,25338,0)
 ;;=V10.62^^147^1587^18
 ;;^UTILITY(U,$J,358.3,25338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25338,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,25338,1,5,0)
 ;;=5^HX OF MYELOID LEUKEMIA
 ;;^UTILITY(U,$J,358.3,25338,2)
 ;;=^295233
 ;;^UTILITY(U,$J,358.3,25339,0)
 ;;=V10.63^^147^1587^17
 ;;^UTILITY(U,$J,358.3,25339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25339,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,25339,1,5,0)
 ;;=5^HX OF MONOCYTIC LEUKEMIA
 ;;^UTILITY(U,$J,358.3,25339,2)
 ;;=^295234
 ;;^UTILITY(U,$J,358.3,25340,0)
 ;;=V10.69^^147^1587^11
 ;;^UTILITY(U,$J,358.3,25340,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25340,1,4,0)
 ;;=4^V10.69
 ;;^UTILITY(U,$J,358.3,25340,1,5,0)
 ;;=5^HX OF LEUKEMIA NEC
 ;;^UTILITY(U,$J,358.3,25340,2)
 ;;=^295235
 ;;
 ;;$END ROU IBDEI1FH
